433 related articles for article (PubMed ID: 17145891)
1. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
2. Role of γδ T cells in α-galactosylceramide-mediated immunity.
Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
[TBL] [Abstract][Full Text] [Related]
3. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
[TBL] [Abstract][Full Text] [Related]
4. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM; Palmer JL; Gamelli RL; Faunce DE
Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
[TBL] [Abstract][Full Text] [Related]
5. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
[TBL] [Abstract][Full Text] [Related]
6. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
7. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
[TBL] [Abstract][Full Text] [Related]
8. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
Biburger M; Tiegs G
J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
[TBL] [Abstract][Full Text] [Related]
9. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice.
Hong S; Wilson MT; Serizawa I; Wu L; Singh N; Naidenko OV; Miura T; Haba T; Scherer DC; Wei J; Kronenberg M; Koezuka Y; Van Kaer L
Nat Med; 2001 Sep; 7(9):1052-6. PubMed ID: 11533710
[TBL] [Abstract][Full Text] [Related]
10. Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide.
Morishima Y; Ishii Y; Kimura T; Shibuya A; Shibuya K; Hegab AE; Iizuka T; Kiwamoto T; Matsuno Y; Sakamoto T; Nomura A; Taniguchi M; Sekizawa K
Eur J Immunol; 2005 Oct; 35(10):2803-14. PubMed ID: 16163669
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
[TBL] [Abstract][Full Text] [Related]
12. Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis.
Kawakami K; Kinjo Y; Yara S; Uezu K; Koguchi Y; Tohyama M; Azuma M; Takeda K; Akira S; Saito A
Infect Immun; 2001 Nov; 69(11):6643-50. PubMed ID: 11598033
[TBL] [Abstract][Full Text] [Related]
13. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
Fujii S; Shimizu K; Kronenberg M; Steinman RM
Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
[TBL] [Abstract][Full Text] [Related]
14. [Repeated administration of alpha-galactosyl ceramide attenuates of natural killer T cells].
Minagawa M; Iiai T; Sato Y; Yamamoto S; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1553-5. PubMed ID: 16315866
[TBL] [Abstract][Full Text] [Related]
15. Cytokine production and migration of in vitro-expanded NK1.1(-) invariant Valpha14 natural killer T (Valpha14i NKT) cells using alpha-galactosylceramide and IL-2.
Ikarashi Y; Iizuka A; Heike Y; Yoshida M; Takaue Y; Wakasugi H
Immunol Lett; 2005 Nov; 101(2):160-7. PubMed ID: 16054231
[TBL] [Abstract][Full Text] [Related]
16. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells.
Kitamura H; Ohta A; Sekimoto M; Sato M; Iwakabe K; Nakui M; Yahata T; Meng H; Koda T; Nishimura S; Kawano T; Taniguchi M; Nishimura T
Cell Immunol; 2000 Jan; 199(1):37-42. PubMed ID: 10675273
[TBL] [Abstract][Full Text] [Related]
17. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
Cullen R; Germanov E; Shimaoka T; Johnston B
J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206
[TBL] [Abstract][Full Text] [Related]
18. Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes.
Ohtaki H; Ito H; Ando K; Ishikawa T; Saito K; Imawari M; Yokochi T; Moriwaki H; Seishima M
Biochem Biophys Res Commun; 2009 Jan; 378(3):579-83. PubMed ID: 19056341
[TBL] [Abstract][Full Text] [Related]
19. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
[TBL] [Abstract][Full Text] [Related]
20. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice.
Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N
J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
